- Home
- NUW vs LUNG Comparison
NUW vs LUNG Comparison
Compare NUW & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- LUNG
- Stock Information
- Founded
- NUW 2008
- LUNG 1995
- Country
- NUW United States
- LUNG United States
- Employees
- NUW N/A
- LUNG N/A
- Industry
- NUW Investment Managers
- LUNG Industrial Specialties
- Sector
- NUW Finance
- LUNG Health Care
- Exchange
- NUW Nasdaq
- LUNG Nasdaq
- Market Cap
- NUW 246.1M
- LUNG 251.5M
- IPO Year
- NUW N/A
- LUNG 2020
- Fundamental
- Price
- NUW $13.37
- LUNG $6.23
- Analyst Decision
- NUW
- LUNG Buy
- Analyst Count
- NUW 0
- LUNG 6
- Target Price
- NUW N/A
- LUNG $11.92
- AVG Volume (30 Days)
- NUW 45.3K
- LUNG 252.9K
- Earning Date
- NUW 01-01-0001
- LUNG 02-19-2025
- Dividend Yield
- NUW 3.66%
- LUNG N/A
- EPS Growth
- NUW N/A
- LUNG N/A
- EPS
- NUW N/A
- LUNG N/A
- Revenue
- NUW N/A
- LUNG $79,302,000.00
- Revenue This Year
- NUW N/A
- LUNG $22.26
- Revenue Next Year
- NUW N/A
- LUNG $18.72
- P/E Ratio
- NUW N/A
- LUNG N/A
- Revenue Growth
- NUW N/A
- LUNG 22.34
- 52 Week Low
- NUW $12.45
- LUNG $5.46
- 52 Week High
- NUW $14.44
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- NUW 31.60
- LUNG 41.37
- Support Level
- NUW $13.40
- LUNG $5.72
- Resistance Level
- NUW $13.99
- LUNG $6.28
- Average True Range (ATR)
- NUW 0.11
- LUNG 0.40
- MACD
- NUW -0.05
- LUNG -0.03
- Stochastic Oscillator
- NUW 11.76
- LUNG 19.85
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.